Ventus Therapeutics Inc., a Waltham, Mass.- and Montreal-based startup developing treatments for autoimmune diseases, inflammatory diseases and cancer, closed a $140 million Series C round. SoftBank Vision Fund 2 and RA Capital Management co-led the funding, which included participation from Qatar Investment Authority, Andreessen Horowitz, BVF Partners, Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, Alexandria Venture Investments, GV and Versant Ventures.
Endeavor BioMedicines, a San Diego-based startup focused on precision treatments for terminal conditions including cancer and fibrosis, completed a $101 million Series B round led by Ally Bridge Group and Avidity Partners. New investors including Perceptive Advisors, Piper Heartland Healthcare Capital and Revelation Partners also participated in the funding, along with previous backers Omega Funds and Longitude Capital. Ally Bridge Group’s Andrew Lam and Avidity Partners’ Monal Mehta will join Endeavor’s board.
Congruence Therapeutics, a Montreal-based startup focused on developing novel small molecules for diseases of protein misfolding, landed $50 million in Series A funding. Amplitude Ventures and Fonds de solidarité FTQ led the round, which included additional support from Lumira Ventures, Investissement Quebec, OrbiMed Advisors, Driehaus Capital Management and others. Alongside the investment, the company appointed Kenneth J. Valenzano as chief scientific officer. He was most recently senior vice president of drug discovery at Amicus Therapeutics.
Scopio Labs, a Tel Aviv-based technology platform for digitizing, quantifying and analyzing hematology and other digital cytology samples, picked up a $50 million Series C investment from OurCrowd, Aurum Ventures and others.
HealthCare.com, a health insurance platform headquartered in New York and Miami, added $31.5 million in new funding from Hildred Capital Management, bringing the round total to $211.5 million. Oaktree Capital Management led the Series C round, which saw additional participation from AXIS Capital, Second Alpha and Link Ventures. Hildred’s David Solomon joined the company’s board.
Ada Health GmbH, a Berlin-based health assessment and care navigation provider, added $30 million in Series B funding from Farallon Capital, Red River West and Bertelsmann Investments to close the round at $120 million. Investors including Leaps by Bayer, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures participated in the initial Series B tranche last year.
Day Zero Diagnostics Inc., a Boston-based startup developing a diagnostic system for bloodstream infections, secured a $21 million funding round. Led by Sands Capital, the investment included contributions from Becton Dickinson & Co., Panacea Venture, Hongkou Capital, Triventures and Golden Seeds. Brooke Story, president of integrated diagnostic solutions at BD, will join the board.
Two precision oncology companies, Imagia Cybernetics and Canexia Health, merged and raised 20 million Canadian dollars (about $16 million) from investors including BDC Capital’s Women in Technology Venture Fund and Desjardins Capital.
Boston Technology Research Corp., a Chelsea, Mass.-based regulatory technology company serving healthcare and life sciences companies, grabbed $15 million in Series A funding. Lead investor Insight Partners was joined by LRVHealth, NewStack Ventures and others in the round.
Expressable, an Austin, Texas-based virtual speech therapy startup, gathered a $15 million Series A round. Led by F-Prime Capital, the investment included participation from Lerer Hippeau, NextView Ventures and Amplifyher Ventures.
Curve Health, a senior-care provider, snagged $12 million in Series A funding. Morningside Ventures led the investment, which included support from Alumni Ventures, Lightspeed Venture Partners, Inflect Health, Correlation Ventures, Rosecliff Venture Partners and Kapor Capital.
Mindstate Design Labs, a Pittsburgh-based startup developing psychedelic-inspired therapeutics for mental health conditions, launched out of stealth with $11.5 million in seed funding. Initialized Capital led the round, which included participation from investors including Metaplanet Holdings, Negev Capital, Day One Ventures, K50 Ventures and Page One Ventures.
Epicore Biosystems Inc., a Cambridge, Mass.-based developer of wearable devices that provide personalized hydration and metabolic monitoring, closed a $10 million Series A round from Chevron Technology Ventures, Alumni Ventures, Joyance Partners and others.
|